[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"menopause-hot-flashes\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:menopause-hot-flashes":167},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,48,80,118,142],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100639584","phase-3-fezolinetant-and-vascular-health-and-brain-health-100639584",false,"NCT07606664","Fezolinetant and Vascular Health and Brain Health","FAVES-B","Inclusion Criteria:\n\n* Born female\n* Age ≥40 - ≤65 years at the time of the screening visit\n* Body Mass Index (BMI) ≥18 to ≤38 kg\u002Fm2\n* Seeking treatment or relief for moderate to severe VMS associated with menopause\n* Confirmed menopausal as per one of the following criteria at the time of screening: Reporting spontaneous amenorrhea for ≥12 consecutive months; spontaneous amenorrhea for ≥6 and \\\u003C 12 months with follicle-stimulating hormone \\>40 IU\u002FL\n* Negative urine pregnancy test at screening (if \\\u003C12 months of amenorrhea)\n* A minimum average of 7-8 moderate to severe VMS per day, or 50-60 per week prior to randomization as reported in the 7-day hot flash diary\n* Agrees to not participate in another interventional study (pharmaceutical or device) while participating in this current study\n\nExclusion Criteria:\n\n* Pregnancy\u002Flactation (past 6 months)\n* Any treatment for hot flashes with demonstrated efficacy for hot flashes\n* Currently using systemic sex-hormone medications.\n* Currently using cytochrome P450 1A2 (CYP1A2) inhibitors (as listed according to the FDA).\n* Severely elevated blood pressure \\[systolic blood pressure (SBP) \\>180 and\u002For diastolic blood pressure (DBP) \\>110\\]\n* A medical condition or chronic disease (including history of hepatic, renal, cardiovascular, gastrointestinal, pulmonary \\[e.g., moderate asthma\\], endocrine or gynecological disease) or malignancy that could confound interpretation of the study in the opinion of the investigator or study physician\n* Self-reported narcolepsy\n* Previous\u002Fcurrent history of a malignant tumor, except for basal cell carcinoma\n* Participants with known cirrhosis, active liver disease, jaundice, or elevated liver aminotransferases or total bilirubin (ALT, AST, and total bilirubin), should not be enrolled if ALT or AST is ≥ 2 x ULN or if the total bilirubin is ≥ 2 x ULN for the evaluating laboratory. Participants with ALP \\> 1.5 × ULN and judged clinically significant by the study physician.\n* Severe renal impairment \\[estimated glomerular filtration rate (eGFR) 15 to \\\u003C30 mL\u002Fmin per 1.73 m2\\] or end-stage renal disease (ESRD) (eGFR \\\u003C 15 mL\u002Fmin\u002F1.73 m2) at screening as per USPI\n* Positive Hepatitis C virus antibody, Hepatitis B surface antigen, and\u002For human immunodeficiency virus antibody screen at screening\n* History within the last 6 months of undiagnosed uterine bleeding\n* Key medical conditions (history of cardiovascular disease, stroke\u002Fcerebrovascular accident, brain injury with loss of consciousness for more than 60 seconds within the last five years, cognitive disorders, brain tumor, dementia, Parkinson's disease, chemotherapy, psychotic disorders)\n* Metal in the body, claustrophobia, or cannot undergo 3T magnetic resonance imaging (MRI); Inability to meet MRI eligibility criteria\n* Lymph node removal on both sides of the body, mastectomy, or dialysis\n* Hysterectomy; levonorgestrel-releasing intrauterine systems initiated before 12 months of spontaneous amenorrhea (Not exclusionary if placed after 12 months of spontaneous amenorrhea), or history of endometrial ablation will be excluded due to inability to stage menopause; Bilateral oophorectomy if completed prior to 12 months of spontaneous amenorrhea\n* Cardiovascular medication use.\n* Prior exposure to fezolinetant or elinzanetant\n* Current participation in another interventional study or participated in an interventional study or received any investigational drug within 3 months\n* Illicit substance use reported in the past week or detected by urine toxicology screen.\n* Subject has any condition, which in the investigator's or study physician's opinion, makes the subject unsuitable for study participation.","FEMALE","40 Years","65 Years",{"count":20,"type":21},220,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The goal of this clinical trial is to learn whether a study drug called fezolinetant impacts cardiovascular and cognitive health in women who have moderate to severe menopausal hot flashes and night sweats.\n\nResearchers will compare fezolinetant to a placebo. A placebo is a pill that looks like the study drug but does not contain any active medicine. This comparison helps researchers understand whether fezolinetant works better than no treatment.\n\nParticipants will:\n\nBe randomly assigned to take either fezolinetant (45 mg) or a placebo once a day for 12 weeks.\n\nVisit the research clinic for regular checkups and tests during the study. Complete tests that measure blood vessel function and cognition.\n\nParticipants and study staff will not know which treatment each participant receives during the study.",[27],"Menopause Hot Flashes",[29,30,31,32,33,34],"menopause","hot flashes","vascular health","brain health","women's health","cognition","NOT_YET_RECRUITING","2026-08-17",{"date":38,"type":39},"2026-08-19","ACTUAL",{"date":41,"type":21},"2026-09-25",{"date":43,"type":21},"2029-12-30",{"name":45,"class":46},"Rebecca Thurston","OTHER",2,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":16,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":79},"100609735","phase-4-the-effect-of-tirzepatide-on-menopausal-vasomotor-symptoms-and-biological-aging-in-post-menopausal-women-with-obesity-100609735","NCT07218445","The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity","The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity: A Pilot Study","Inclusion Criteria\n\n1. Females\n2. Age 46-60 years old.\n3. BMI ≥30 kg\u002Fm2 or BMI ≥27 kg\u002Fm2 in the presence of adiposity-associated diseases (hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease).\n4. Presence of bothersome hot flashes (an average of ≥ 28 episodes during a consecutive 2-week period with symptom severity sufficient to have prompted the participant to seek therapeutic treatment).\n5. Hot flashes must be present for \\>30 days prior to study entry.\n6. Willingness to self-inject drug\n7. Provided informed consent to be part of the study.\n8. Willingness and capability to follow an individualized hypocaloric diet designed to achieve an approximate energy deficit of 500 kcal\u002Fday relative to estimated total daily energy requirements. Daily energy requirements will be calculated using Harris-Benedict equation to estimate resting energy expenditure and multiplied by a sedentary physical activity factor of 1.2. Prescribed daily caloric intake will not be less than 1,000 kcal\u002Fday. Participants must also be willing to engage in at least 150 minutes per week of moderate-intensity or greater physical activity.\n\nExclusion Criteria\n\n1. Current or recent use (past 4 weeks) treatment with menopausal hormone therapy.\n2. Any current, recent use (past 4 weeks), or planned use of:\n\n   1. Estrogen-containing contraceptive methods or menopausal hormone therapy (oral, transdermal, high dose vaginal ring, injection, pellets).\n   2. Vaginal estrogen.\n   3. Androgens.\n   4. Progestogens.\n3. Current or recent use (past 4 weeks) treatment for menopausal symptoms with cognitive behavioral therapy and\u002For hypnosis.\n4. Current or recent use (past 4 weeks) of fezolinetant or elinzanetant.\n5. Menopause as a result of cancer treatments.\n6. Impaired renal function (GFR ≤30 ml\u002Fmin\u002F1.73 m²).\n7. Thyroid-stimulating hormone ≥7 with low free T4.\n8. 10-year ASCVD risk \\> 7.5%.\n9. Active inflammatory, autoimmune, infectious, hepatic, gastrointestinal, malignancy, or uncontrolled psychiatric disease.\n10. \\>5% change in weight during the 3 months prior to screening and, or eight fluctuation of ≥20 pounds within the past 6 months (self-report).\n11. Other obesity medication was used within the past 3 months.\n12. History of bariatric surgery. Prior or planned surgical treatment for obesity (excluding liposuction or abdominoplasty performed \\> 1 year before screening).\n13. Past or intended endoscopic and\u002For device-based therapy or removal within last six months.\n14. Use of weight gain-promoting medications (including tricyclic antidepressants, atypical antipsychotics, and mood stabilizers), unless the participant has been receiving the medication at a stable dose for ≥3 months prior to enrollment and has maintained a stable body weight during that time\n15. Current or recent (within 3 months) use of chronic systemic glucocorticoid therapy for over 2 weeks within the past 3 months.\n16. Female who is pregnant, breastfeeding, or intends to become pregnant or is of child-bearing potential and not using a highly effective contraceptive method.\n17. Contraindications to GLP-1 receptor agonist therapy as per Tirzepatide (Zepbound ®) label, including a personal or family history of medullary thyroid carcinoma; a history or diagnosis of multiple endocrine neoplasia syndrome type 2; known hypersensitivity to tirzepatide or any of its excipients.\n18. Currently enrolled in another clinical study involving an investigational product or participated in one and received treatment (active or placebo) in the last 30 days.\n19. Planned surgical procedures requiring general anesthesia or sedation during the study or within 2 weeks following the last dose of study drug.",true,"46 Years","60 Years",{"count":59,"type":21},40,[61],"PHASE4","The purpose of this study is to determine the effect of tirzepatide on vasomotor symptoms and on measures of biological aging.",[64,27],"Obesity",[66,29,67,68],"Hot flashes","Tirzepatide","GLP","RECRUITING","2026-08-16",{"date":72,"type":39},"2026-08-18",{"date":74,"type":39},"2026-04-08",{"date":76,"type":21},"2027-09-18",{"name":78,"class":46},"Mayo Clinic",1,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":16,"minAge":88,"maxAge":18,"enrollmentInfo":89,"targetDuration":4,"studyType":22,"phases":91,"briefSummary":93,"conditions":94,"keywords":97,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":79},"100650561","haelan-951-for-menopause-symptoms-in-peri--and-postmenopausal-women-100650561","NCT07751029","Haelan 951 for Menopause Symptoms in Peri- and Postmenopausal Women","A Decentralized, Site-Anchored Hybrid, Open-Label, Single-Arm Proof-of-Concept Study Evaluating the Effect of Haelan 951 - a Fermented Soy Conventional Food Product - on Self-Reported Menopausal Vasomotor and Sleep-Related Outcomes in Post- and Peri-Menopausal Women","H951-MENO","Inclusion Criteria:\n\n1. Female sex assigned at birth, ages 45-65 years inclusive at the time of consent.\n2. Post-menopausal (≥12 consecutive months amenorrhea, STRAW+10 stage +1) OR peri-menopausal (STRAW+10 stages -2 or -1) at consent. PI to confirm staging at Screening.\n3. Self-reported vasomotor symptoms ≥3 months' duration prior to Screening, averaging ≥4 episodes per 24-hour period over the 7 days prior to Screening.\n4. Willing and able to consume the investigational product as directed (30 mL twice daily, empty stomach, 30 days).\n5. Willing and able to complete daily eCOA entries in the study application and to wear the study wearable throughout the Treatment period.\n6. Possession of (or willingness to use) a personal smartphone running iOS 16+ or Android 12+, with reliable daily internet access.\n7. Resident of the Kansas City metropolitan area \\[30- 45 mile radius\\] and able to travel to Spectrum Clinical Research for a single onsite Participant Onboarding Visit.\n8. Able to read, understand, and provide written informed consent in English at approximately an 8th-grade reading level.\n9. Willing to abstain from initiation of any new HRT, menopause-related supplement, or other menopause-related therapeutic intervention for the study duration.\n\nExclusion Criteria:\n\n1. Pre-menopausal status (STRAW+10 stage -3 or earlier).\n2. Current pregnancy, planning pregnancy during the study, or breastfeeding.\n3. Current use of any systemic or topical HRT. Required wash-out prior to Day 1: 30 days systemic and 30 days topical\u002Flocal, aligned with the Screening period and the 30-day study duration; the PI may extend for an individual on documented clinical rationale per ICH E6(R3) 4.2.1.\n4. Current use of any menopause-related dietary supplement within 30 days prior to Day 1, unless on a stable regimen ≥3 months and willing to maintain it unchanged (documented in medical history).\n5. Known soy allergy or hypersensitivity to any component of Haelan 951 (Purified Water, Organic Cultured Soy Powder, Yeast, Salt).\n6. History of estrogen- or progesterone-receptor-positive breast cancer; active malignancy of any type; or current systemic chemotherapy, immunotherapy, or radiation therapy.\n7. Heavy alcohol use (≥3 alcoholic beverages\u002Fday on average, per NIAAA definitions).\n8. Major surgical procedure or hospitalization within 90 days prior to Screening, or any unresolved condition that the PI judges would compromise safety or interpretation of endpoints.\n9. Documented uncontrolled or unstable medical condition (e.g., uncontrolled cardiovascular disease; CKD stage 3b or worse; moderate-to-severe hepatic impairment; active autoimmune disease on systemic immunosuppression), established from medical history and PI clinical assessment.\n10. Current use of medications with documented potential for clinically significant interaction with soy-derived foods (thyroid replacement unless dose-stable ≥6 weeks with 4-hour separation; oral anticoagulants on non-stable dose; MAOIs; tamoxifen or other hormone-modulating cancer therapies).\n11. Current or recent (within 30 days) participation in another interventional clinical study.\n12. Inability to provide informed consent (cognitive impairment, language barrier - materials are English-only - or other reason per PI judgment).\n13. Other reasons judged by the PI, with documented rationale per ICH E6(R3) 4.2.1, to compromise safety, well-being, or scientific validity.","45 Years",{"count":90,"type":21},25,[92],"NA","This proof-of-concept, open-label, single-arm study is designed to evaluate the effects of daily consumption of Haelan 951, a fermented soy conventional food product, on self-reported menopausal vasomotor symptoms, sleep quality, and health-related quality of life in peri- and postmenopausal women. The study will collect descriptive data on participant-reported outcomes over the study period to assess the feasibility and potential effects of Haelan 951 in supporting menopausal wellness. The study is not intended to evaluate the treatment, prevention, or cure of any disease.",[95,27,96],"Menopause","Menopause Related Conditions",[95,98,99,100,101,102,103,104,105,106,107],"Perimenopause","Vasomotor Symptoms","Hot Flashes","Sleep Quality","Quality of Life","Haelan 951","Fermented Soy","Conventional Food","Decentralized Clinical Trial","Wearable Technology","2026-08-06",{"date":110,"type":39},"2026-08-10",{"date":112,"type":21},"2026-08",{"date":114,"type":21},"2026-10",{"name":116,"class":117},"Spectrum Clinical Research, LLC","NETWORK",{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":55,"sex":16,"minAge":88,"maxAge":124,"enrollmentInfo":125,"targetDuration":4,"studyType":22,"phases":127,"briefSummary":129,"conditions":130,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":141},"100591029","phase-2-focusing-on-the-menopausal-transition-to-improve-mid-life-womens-health-100591029","NCT06975111","Focusing on the Menopausal Transition to Improve Mid-Life Women's Health","Inclusion Criteria:\n\n* aged 45-55\n* In the late menopausal transition, defined as 60 days of amenorrhea but less than 365 days of amenorrhea18\n* No current use of hormone therapy or hormonal contraception\n* Presence of a uterus and at least one ovary in order to track menstrual patterns\n* Have a smartphone and broadband access adequate to accept telehealth appointments\n\nExclusion Criteria:\n\n* Lack of broadband access (activity and survey data will be collected electronically whenever possible and some visits will be via telehealth)\n* Lack of regular menstrual periods in mid-reproductive life (ages 25-38) when not on hormones or not pregnant.\n* Pregnancy or actively trying to get pregnant\n* Inability to adhere to study protocol schedule\n* Untreated alcoholism\n* Un- Diagnosed abnormal uterine bleeding\n* Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia (MEN 2) for participants with a BMI\\> 30 kg\u002Fm2.","55 Years",{"count":126,"type":21},200,[128,24],"PHASE2","What if midlife women, who are inherently at an increased risk for future cardiometabolic disease due to transitioning into menopause, had access to a suite of evidence-based health interventions? Could these interventions reduce menopause-related inflammation, restore a healthier cardiometabolic profile, reverse epigenetic aging, and reduce bothersome menopausal symptoms? The ultimate goal of this work is to attenuate future disease and enhance women's quality of life, extend healthspan and increase productivity.",[95,27,96,131],"Cardiovascular","2026-07-17",{"date":134,"type":39},"2026-07-21",{"date":136,"type":39},"2026-03-01",{"date":138,"type":21},"2030-10-01",{"name":140,"class":46},"University of Colorado, Denver",3,{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":57,"enrollmentInfo":148,"targetDuration":4,"studyType":22,"phases":150,"briefSummary":151,"conditions":152,"keywords":154,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":4},"100621831","transcranial-electrical-stimulation-for-noninvasive-study-of-menopausalperimenopausal-symptoms-100621831","NCT07375732","Transcranial Electrical Stimulation for Noninvasive Study of Menopausal\u002FPerimenopausal Symptoms","Inclusion Criteria:\n\n* Age between 40 and 60 years\n* Participants falling under stages -2 to +2 in the Stages of Reproductive Aging Workshop (STRAW +10) as defined below:\n* Early menopause transition (Stage -2): Increased variability in menstrual cycle defined as persistent difference of 7 days or more in the length of consecutive cycles. Persistence is defined as recurrence within 10 cycles of the first variable cycle.\n* Late menopause transition (Stage -1): Occurrence of amenorrhea of 60 days or longer.\n* Final Menstrual Period (Stage 0): Have undergone 12 consecutive months without a menstrual period, not due to other medical causes.\n* Early Postmenopause (Stage +1): 5-8 years after final menstrual period.\n* Late Postmenopause (Stage +2): \\>8 years after final menstrual period.\n* Participants having frequent hot flashes (at least once a day).\n\nExclusion Criteria:\n\n* Disorders that may mask or coincide with menopause and peri-menopause, such as: Primary Ovarian Insufficiency, Thyroid disease (Hyper\u002Fhypothyroidism), Hyperprolactinemia, Cushing's syndrome, Endometrial\u002FOvarian Cancer, Polycystic Ovary Syndrome (PCOS), Functional hypothalamic amenorrhea\n* Concurrent drugs:\n* GnRH agonist\u002Fantagonist\n* Tamoxifen\u002Faromatase inhibitors\n* Other conditions: Recent hematoma (\\\u003C48 hours), History of hemorrhagic disorders (any platelet disorder (ITP, TTP, HUS, Glanzmann thrombasthenia), Hemophilia A\u002FB, history of arterial insufficiency, any prior history of malignancy, current pregnancy, a lifetime history of severe, uncontrolled mood disorders (anxiety, depression, bipolar), psychotic disorders, other neural disorders, or heart disease, any condition that makes them unable to perform tasks outlined in experiment, tattoos on sensory testing sites.",{"count":149,"type":21},50,[92],"Participants are being invited to a research study. This research aims to assess the tolerability of transcranial electrical stimulation of the brain, and explore the response of TES on menopausal\u002Fperimenopausal symptoms including hot flashes effects, depression\u002Fanxiety, memory-problems, and muscular problems. This study will assess what types of electrical brain stimulation affect different menopausal related symptoms. This study will help guide the development of electrical stimulation to be used for improving women's health during menopause transition.",[153,27,95,96],"Menopausal Depression",[155,156,157,99,100],"Noninvasive Neuromodulation","Transcranial Electrical Stimulation","Depression","2026-01-26",{"date":160,"type":39},"2026-01-29",{"date":162,"type":21},"2026-02",{"date":164,"type":21},"2027-04",{"name":166,"class":46},"Carnegie Mellon University","Menopause-Hot Flashes"]